Volker Gross

Summary

Affiliation: Klinikum St. Marien
Country: Germany

Publications

  1. doi request reprint [Immunosuppression in inflammatory bowel disease: When, how and how long?]
    V Gross
    Medizinische Klinik II, Klinikum St Marien Amberg
    Dtsch Med Wochenschr 137:1803-5. 2012
  2. doi request reprint Aminosalicylates
    Volker Gross
    Medizinische Klinik 2, Klinikum St Marien, Amberg, Deutschland
    Dig Dis 30:92-9. 2012
  3. ncbi request reprint Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis
    V Gross
    Hospital St Marien, Amberg, Germany
    Aliment Pharmacol Ther 23:303-12. 2006
  4. doi request reprint Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis
    Volker Gross
    Medizinische Klinik II, Klinikum St Marien, Mariahilfbergweg 7, D 92224 Amberg, Germany
    Expert Opin Pharmacother 9:1257-65. 2008
  5. doi request reprint [Diverticular disease and diverticulitis]
    V Gross
    Medizinische Klinik II, Klinikum St Marien, Mariahilfbergweg 7, 92224 Amberg, Deutschland
    Dtsch Med Wochenschr 133:1437-46. 2008
  6. ncbi request reprint [Diagnostic workup of chronic diarrhoea]
    V Gross
    Med Kinik II, Klinikum St Marien, Amberg
    MMW Fortschr Med 150:41-3. 2008
  7. doi request reprint 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial
    Volker Gross
    Medizinische Klinik II, Klinikum St Marien, Mariahilfbergweg 5 7, 92224 Amberg, Germany
    J Crohns Colitis 5:129-38. 2011
  8. doi request reprint Topical therapy
    Volker Gross
    Medizinische Klinik II, Klinikum St Marien, Amberg, Deutschland gross volker klinikum amberg de
    Dig Dis 30:92-9. 2012
  9. ncbi request reprint Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease
    Cornelia M Gelbmann
    Department of Internal Medicine I, University of Regensburg, Germany
    Am J Gastroenterol 97:1438-45. 2002

Detail Information

Publications9

  1. doi request reprint [Immunosuppression in inflammatory bowel disease: When, how and how long?]
    V Gross
    Medizinische Klinik II, Klinikum St Marien Amberg
    Dtsch Med Wochenschr 137:1803-5. 2012
    ..Current guidelines set the frame for the rational use of these drugs...
  2. doi request reprint Aminosalicylates
    Volker Gross
    Medizinische Klinik 2, Klinikum St Marien, Amberg, Deutschland
    Dig Dis 30:92-9. 2012
    ..In segmental colitis associated with diverticulosis no prospective systematic studies are available. However, several case reports show a high efficacy of mesalazine in segmental colitis associated with diverticulosis...
  3. ncbi request reprint Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis
    V Gross
    Hospital St Marien, Amberg, Germany
    Aliment Pharmacol Ther 23:303-12. 2006
    ..Rectal budesonide is an effective treatment of active ulcerative proctitis or proctosigmoiditis...
  4. doi request reprint Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis
    Volker Gross
    Medizinische Klinik II, Klinikum St Marien, Mariahilfbergweg 7, D 92224 Amberg, Germany
    Expert Opin Pharmacother 9:1257-65. 2008
    ..Budesonide is a glucocorticoid with high topical glucocorticoid activity and low systemic availability. Oral pH-modified release budesonide has been investigated for the treatment of various inflammatory intestinal diseases...
  5. doi request reprint [Diverticular disease and diverticulitis]
    V Gross
    Medizinische Klinik II, Klinikum St Marien, Mariahilfbergweg 7, 92224 Amberg, Deutschland
    Dtsch Med Wochenschr 133:1437-46. 2008
  6. ncbi request reprint [Diagnostic workup of chronic diarrhoea]
    V Gross
    Med Kinik II, Klinikum St Marien, Amberg
    MMW Fortschr Med 150:41-3. 2008
  7. doi request reprint 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial
    Volker Gross
    Medizinische Klinik II, Klinikum St Marien, Mariahilfbergweg 5 7, 92224 Amberg, Germany
    J Crohns Colitis 5:129-38. 2011
    ..Budesonide may be an effective therapy for mild-to-moderately active ulcerative colitis (UC). This study aimed to demonstrate non-inferiority for oral 9mg budesonide once daily (OD) versus 3g mesalazine granules OD...
  8. doi request reprint Topical therapy
    Volker Gross
    Medizinische Klinik II, Klinikum St Marien, Amberg, Deutschland gross volker klinikum amberg de
    Dig Dis 30:92-9. 2012
    ..To overcome adherence problems with rectal therapy, rectal foam preparations have been developed which are usually better tolerated than enemas...
  9. ncbi request reprint Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease
    Cornelia M Gelbmann
    Department of Internal Medicine I, University of Regensburg, Germany
    Am J Gastroenterol 97:1438-45. 2002
    ..Some patients with Crohn's disease (CD) do not respond to corticosteroid therapy. Furthermore, corticosteroids frequently cause side effects. Thus, predictive parameters for treatment refractoriness would be helpful for treatment decisions...